The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Sulphasalazine and mesalazine: serious adverse reactions re-evaluated on the basis of suspected adverse reaction reports to the Committee on Safety of Medicines
Open accessAbstract
We were interested to read the report by Ransford and Langman of their analysis of yellow card reports of suspected adverse drugs reactions for sulphasalazine and mesalazine ( Gut2002;51:536–9 [OpenUrl][1][Abstract/FREE Full Text][2] ). These reports, submitted to the Committee on Safety of Medicines, may provide useful flags to signal unrecognised hazards of drugs. However, as adverse reactions are not always recognised or reported to the regulatory authorities by physicians, these reports usually underestimate the frequency of any adverse drug reaction. Of greater importance, underreporting is usually not random but selective, which may introduce serious bias when comparing different drugs.1 Various examples have been described previously of drugs that showed substantive differences in reporting rates, which were not substantiated after further research.1 For this reason, it is recommended that, once there is a signal for a suspected adverse drug reaction, other sources of data are investigated.2 We recently initiated a study to quantify the risk of renal toxicity in patients taking aminosalicylate (5-ASA) drugs in the UK. The General Practice Research Database (GPRD) was used for this study, … [1]: {openurl}?query=rft.jtitle%253DGut%26rft.stitle%253DGut%26rft.issn%253D0017-5749%26rft.aulast%253DRansford%26rft.auinit1%253DR%2BA%2BJ%26rft.volume%253D51%26rft.issue%253D4%26rft.spage%253D536%26rft.epage%253D539%26rft.atitle%253DSulphasalazine%2Band%2Bmesalazine%253A%2Bserious%2Badverse%2Breactions%2Bre-evaluated%2Bon%2Bthe%2Bbasis%2Bof%2Bsuspected%2Badverse%2Breaction%2Breports%2Bto%2Bthe%2BCommittee%2Bon%2BSafety%2Bof%2BMedicines%26rft_id%253Dinfo%253Adoi%252F10.1136%252Fgut.51.4.536%26rft_id%253Dinfo%253Apmid%252F12235076%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx [2]: /lookup/ijlink?linkType=ABST&journalCode=gutjnl&resid=51/4/536&atom=%2Fgutjnl%2F52%2F10%2F1530.atom
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Evans, S. J. W., Waller, P. C., & Davis, S. (2001) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.677 · Cited by 1,802
AN EXPERIMENT TO DETERMINE THE ACTIVE THERAPEUTIC MOIETY OF SULPHASALAZINE
Khan, A. K. A., Piris, J., & Truelove, S. C. (1977) · The Lancet · doi:10.1016/s0140-6736(77)90831-5 · Cited by 814
Reubi, J., Waser, B., Schaer, J.-C., & Laissue, J. A. (2001) · European Journal of Nuclear Medicine · doi:10.1007/s002590100541 · Cited by 657
The UK General Practice Research Database
Walley, T., & Mantgani, A. (1997) · The Lancet · doi:10.1016/s0140-6736(97)04248-7 · Cited by 623
Guidelines for osteoporosis in coeliac disease and inflammatory bowel disease
Scott, E. M., Gaywood, I., & Scott, B. B. (2000) · Gut · doi:10.1136/gut.46.suppl_1.i1 · Cited by 377
Ransford, R., & Langman, M. J. S. (2002) · Gut · doi:10.1136/gut.51.4.536 · Cited by 355
Vestergaard, P. (2002) · American Journal of Epidemiology · doi:10.1093/aje/kwf007 · Cited by 321
Treatment of hepatocellular carcinoma with octreotide: a randomised controlled study
Kouroumalis, E., Skordilis, P., Thermos, K., Vasilaki, A., Moschandrea, J., & Manousos, O. N. (1998) · Gut · doi:10.1136/gut.42.3.442 · Cited by 280
Riley, S. A., Mani, V, Goodman, M. J., Herd, M. E., Dutt, S., & Turnberg, L. A. (1988) · Gut · doi:10.1136/gut.29.5.669 · Cited by 193
Yuen, M.-F., Poon, R. T.-P., Lai, C.-L., Fan, S.-T., Lo, C.-M., Wong, K.-W., Wong, W. M., & Wong, B. C.-Y. (2002) · Hepatology · doi:10.1053/jhep.2002.35071 · Cited by 184
Riley, S. A., Mani, V., Goodman, M. J., Herd, M. E., Dutt, S., & Turnberg, L. A. (1988) · Gastroenterology · doi:10.1016/0016-5085(88)90677-4 · Cited by 173
Renal and Urologic Complications of Inflammatory Bowel Disease
Pardi, D. S., Tremaine, W. J., Sandborn, W. J., & McCarthy, J. T. (1998) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.1998.156_b.x · Cited by 154
Corrigan, & Stevens (2000) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.2000.00683.x · Cited by 123
Benali, N. L., Cordelier, P., Calise, D., Pagès, P., Rochaix, P., Nagy, A., Estève, J., Pour, P. M., Schally, A. V., Vaysse, N., et al. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.130196697 · Cited by 120
Mesalazine-associated interstitial nephritis
WORLD, M. J., Stevens, P. E., Ashton, M. A., & Rainford, D. J. (1996) · Nephrology Dialysis Transplantation · doi:10.1093/oxfordjournals.ndt.a027349 · Cited by 118
Regulatory peptide receptors in human hepatocellular carcinomas
Reubi, J. C., Zimmermann, A., Jonas, S., Waser, B., Neuhaus, P., Läderach, U., & Wiedenmann, B. (1999) · Gut · doi:10.1136/gut.45.5.766 · Cited by 114
Fockens, P., Mulder, C. J. J., Tytgat, G. N. J., Blok, P., & Ferwerda, J. (1995) · European Journal of Gastroenterology & Hepatology · doi:10.1097/00042737-199511000-00003 · Cited by 103
Primary chronic interstitial nephritis in Crohn's disease
Izzedine, H., Simon, J., Piette, A., Lucsko, M., Baumelou, A., Charitanski, D., Kernaonet, E., Baglin, A., Deray, G., & Beaufils, H. (2002) · Gastroenterology · doi:10.1053/gast.2002.36613 · Cited by 89
Lancashire, R., Cheng, K. K., & Langman, M. J. S. (2003) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.2003.01485.x · Cited by 87
Marteau, P. R., Nelet, F., LU, M. L., & DEVAUX, C. (1996) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.1996.92264000.x · Cited by 81
Hypersensitivity with hepatotoxicity to mesalazine after hypersensitivity to sulfasalazine
Hautekèete, M., Bourgeois, N., Potvin, P., Duville, L., Reynaert, H., Devis, G., Adler, M., & Klöppel, G. (1992) · Gastroenterology · doi:10.1016/0016-5085(92)91453-b · Cited by 57
The Risk of Sulfasalazine‐ and Mesalazine‐Associated Blood Disorders
Jick, H., Myers, M. W., & Dean, A. D. (1995) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/j.1875-9114.1995.tb04352.x · Cited by 53
Keisu, M., & Ekman, E. (1992) · European Journal of Clinical Pharmacology · doi:10.1007/bf02333012 · Cited by 44
Acute Interstitial Nephritis Associated with the Use of Mesalazine in Inflammatory Bowel Disease
Frandsen, N. E., Saugmann, S., & Marcussen, N. (2002) · The Nephron journals/Nephron journals · doi:10.1159/000064461 · Cited by 43
Cited by
Dignass, A., Van Assche, G., Lindsay, J. O., Lémann, M., Söderholm, J., Colombel, J. F., Danese, S., D'Hoore, A., Gassull, M., Gomollón, F., et al. (2010) · Journal of Crohn's and Colitis · doi:10.1016/j.crohns.2009.12.002 · Cited by 1,498
Guidelines for the management of inflammatory bowel disease in adults
Mowat, C., Cole, A., Windsor, A., Ahmad, T., Arnott, I., Driscoll, R., Mitton, S., Orchard, T., Rutter, M., Younge, L., et al. (2011) · Gut · doi:10.1136/gut.2010.224154 · Cited by 1,419
Guidelines for the management of inflammatory bowel disease in adults
Carter, M. J., Lobo, A. J., & Travis, S. P. L. (2004) · Gut · doi:10.1136/gut.2004.043372 · Cited by 1,083
Travis, S. P. L., Stange, E. F., Lémann, M., Öresland, T., Chowers, Y., Forbes, A., D’Haens, G., Kitis, G., Cortot, A., Prantera, C., et al. (2006) · Gut · doi:10.1136/gut.2005.081950b · Cited by 597
Bernstein, C. N., Wajda, A., & Blanchard, J. F. (2005) · Gastroenterology · doi:10.1053/j.gastro.2005.06.021 · Cited by 569
Metadata
- Authors
- Logan, R. F., & van Staa, T. P.
- Venue
- Gut
- Publisher
- BMJ
- Published
- 2003-09-11
- Volume
- 52
- Issue
- 10
- Pages
- 1530-1531
- ISSN
- 0017-5749 (ISSN-L)
- 1468-3288
- OpenAlex
- W2166394537
- Cited by
- 262
- References
- 24
- FWCI
- 19.22
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.